Betmiga mirabegron regulatory update

The U.K.'s NICE issued draft guidance recommending Betmiga mirabegron from Astellas for the symptomatic treatment of overactive bladder (OAB) only in patients for whom antimuscarinic drugs are contraindicated or clinically ineffective or have unacceptable side effects. The committee said Betmiga was "likely to be a cost-effective treatment" in this subset of OAB patients, despite the "uncertain" cost-effectiveness of Betmiga compared with antimuscarinic drugs as a class. Comments are due March 22, with a second appraisal committee meeting scheduled for April 9. ...